← Back to Screener
Daxor Corporation Common Stock (DXR)
Price$9.98
Favorite Metrics
Price vs S&P 500 (26W)-29.41%
Price vs S&P 500 (4W)-13.18%
Market Capitalization$56.03M
P/E Ratio (Annual)6.11x
All Metrics
P/CF (Annual)98.13x
Book Value / Share (Quarterly)$9.07
P/TBV (Annual)2.05x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-51.22%
Cash Flow / Share (Quarterly)$0.11
Price vs S&P 500 (YTD)-36.27%
Gross Margin (TTM)-3917.23%
Net Profit Margin (TTM)34356.61%
EPS (TTM)$1.98
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$1.98
Revenue Growth (5Y)-36.57%
EPS (Annual)$1.81
ROI (Annual)19.98%
Gross Margin (Annual)-3917.23%
Net Profit Margin (5Y Avg)7784.99%
Cash / Share (Quarterly)$0.02
P/E Basic Excl Extra (TTM)6.11x
Revenue Growth QoQ (YoY)-82.61%
P/E Normalized (Annual)6.11x
ROA (Last FY)19.93%
Revenue Growth TTM (YoY)-77.71%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)12.52%
Operating Margin (TTM)-4207.42%
Cash Flow / Share (Annual)$0.11
P/B Ratio1.22x
P/B Ratio (Quarterly)1.59x
EV / Revenue (TTM)2099.12x
Net Interest Coverage (TTM)-0.38x
ROA (TTM)22.39%
EPS Growth QoQ (YoY)329.99%
EV / EBITDA (TTM)5602.55x
EPS Incl Extra (Annual)$1.81
Current Ratio (Annual)0.08x
Quick Ratio (Quarterly)0.08x
3-Month Avg Trading Volume0.01M
52-Week Price Return34.68%
EV / Free Cash Flow (Annual)98.13x
P/E Incl Extra (TTM)6.11x
Tangible BV / Share (Quarterly)$6.33
P/S Ratio (Annual)2099.12x
Asset Turnover (Annual)0.00x
52-Week High$14.76
Operating Margin (5Y Avg)-1352.68%
EPS Excl Extra (Annual)$1.81
Tangible BV CAGR (5Y)16.06%
26-Week Price Return-22.52%
Quick Ratio (Annual)0.08x
13-Week Price Return-27.15%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.08x
Enterprise Value$56.026
Revenue / Share Growth (5Y)-39.61%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)18.24%
Inventory Turnover (Annual)1.86x
Pretax Margin (Annual)34356.58%
Cash / Share (Annual)$0.02
3-Month Return Std Dev41.41%
Gross Margin (5Y Avg)-1212.70%
ROE (Last FY)19.98%
Net Interest Coverage (Annual)-4.58x
EPS Basic Excl Extra (Annual)$1.81
P/FCF (TTM)98.13x
Receivables Turnover (TTM)7.25x
EV / Free Cash Flow (TTM)98.13x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.98
Receivables Turnover (Annual)7.25x
ROI (TTM)22.43%
P/S Ratio (TTM)2099.12x
Pretax Margin (5Y Avg)7784.99%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$7.15
Free OCF CAGR (5Y)-61.68%
Price vs S&P 500 (52W)0.05%
P/E Ratio (TTM)6.11x
EPS Growth TTM (YoY)1068.54%
Year-to-Date Return-32.34%
5-Day Price Return6.40%
EPS Normalized (Annual)$1.81
ROA (5Y Avg)11.66%
Net Profit Margin (Annual)34356.58%
Month-to-Date Return3.21%
EBITD / Share (Annual)$-0.22
EPS Growth (3Y)14.49%
Operating Margin (Annual)-4207.38%
LT Debt / Equity (Annual)0.01x
P/CF (TTM)98.13x
ROI (5Y Avg)11.81%
P/E Excl Extra (TTM)6.11x
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$1.98
P/TBV (Quarterly)1.25x
P/B Ratio (Annual)1.59x
Inventory Turnover (TTM)1.89x
Pretax Margin (TTM)34356.61%
Book Value / Share (Annual)$9.07
Price vs S&P 500 (13W)-29.53%
Beta0.20x
P/FCF (Annual)98.13x
Revenue / Share (TTM)$0.01
ROE (TTM)22.50%
52-Week Low$7.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
DXRDaxor Corporation Common Stock | 2099.12x | -36.57% | -3917.23% | -4207.42% | $9.98 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Daxor Corp is a medical instrumentation company specializing in blood volume diagnostics. The company develops and markets the BVA-100 (Blood Volume Analyzer), an FDA-cleared diagnostic tool that provides accurate, objective measurement of blood volume status and composition across a broad range of medical conditions. By comparing results to patient-specific norms, the BVA-100 enables clinicians to make data-driven treatment decisions.